Step 1: Understand the assertion.
Hormone replacement therapy (HRT) with systemic, that is oral, estrogen is used in post-menopausal women mainly to relieve symptoms like hot flashes and to protect bone density. The assertion claims it is indicated specifically in women who already have high triglyceride levels. This does not match standard practice, where high triglycerides or a personal history of pancreatitis are treated as a caution or contraindication for oral estrogen, not an indication for it. So the assertion is false.
Step 2: Understand the reason.
Oral estrogen passes through the liver first before reaching the rest of the body, a route called the first-pass effect. In the liver, estrogen stimulates the production of lipoproteins, particularly triglyceride-rich VLDL particles. This raises circulating triglyceride levels. This is a well-established pharmacological fact, so the reason is true.
Step 3: Connect the two statements.
Because oral estrogen raises triglycerides through increased hepatic lipoprotein synthesis, giving it to a woman who already has high triglycerides can push her levels even higher, raising the risk of pancreatitis. This is exactly why oral estrogen is generally avoided, or non-oral routes like transdermal patches are preferred instead, in women with hypertriglyceridemia. So the reason correctly explains why the assertion is false, not why it is true.
Step 4: Rule out the other options.
Options (a) and (b) both require A to be true, which it is not. Option (c) requires R to be false, but R is a correct pharmacological fact.
Final Answer:
A is false but R is true.